Radioimmunodetection with 111 In–labeled Monoclonal Antibody Nd2 in Patients with Pancreatic Cancer

This report summarizes results from an initial clinical evaluation of radioimnumodetection (RAID) in patients with pancreatic cancer using murine monoclonal antibody Nd2, directed against mucins from pancreatic cancer.Nd2 (2 mg) was labeled with 111ln (2 mCi) and injected into 19 patients suspected...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 1997-04, Vol.88 (4)
Main Authors: Yong‐Suk Chung, Sawada, Tetsuji, Kondo, Yasuyuki, Hirayama, Koji, Inui, Akimasa, Yamashita, Yoshito, Nakata, Bunzo, Okamura, Terue, Ochi, Hironobu, Ho, Jenny J L, Kim, Young S, Sowa, Michio
Format: Article
Language:English
Subjects:
Carcinoma
Monoclonal antibodies
Mucin
Pancreatic cancer
Pancreatitis
Patients
Surgery
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This report summarizes results from an initial clinical evaluation of radioimnumodetection (RAID) in patients with pancreatic cancer using murine monoclonal antibody Nd2, directed against mucins from pancreatic cancer.Nd2 (2 mg) was labeled with 111ln (2 mCi) and injected into 19 patients suspected of having pancreatic cancer. Planar scintigrams were taken 3 days post–infusion. As for final diagnoses after surgery, 14 cases were pancreatic cancer, and one case each was chronic pancreatitis, neurilem–moma, islet cell carcinoma, cholangioma, and apparent absence of suspected recurrent lesion of pancreatic cancer. Of 14– patients with pancreatic cancer, RAID was positive in 10 cases (71.4%). Cases other than pancreatic cancer were all negative, so the specificity was 100%. These results demonstrate that RAID using 111In–Nd2 can be useful in differentiating exocrine pancreatic cancer from benign conditions and other types of carcinomas in the pancreatoduodenal regions.
ISSN:1347-9032
1349-7006